Eli Lilly confirmed on August 3, 2026 that patients can now apply for early access to retatrutide, its unapproved triple-agonist obesity drug, roughly six weeks after STAT News revealed the company had quietly granted access to a single 79-year-old patient. The company's statement was short: "For a limited number of patients who meet specific medical criteria and cannot enroll in a clinical trial, we believe it is medically appropriate to make authentic retatrutide available before FDA approval, consistent with FDA's guidance."
The important part is the phrase "specific medical criteria." Four requirements gate the program, three separate parties have to approve each request, and there is no published appeals process. Three weeks in, the picture from clinicians is that the door opened — but only about as wide as it was before.
Research-context information only. Retatrutide is an investigational drug not approved by the FDA. The program details, criteria, and sourcing realities described below are reported from public coverage and company statements — they are not endorsed and not medical advice. Possession or use of investigational drugs outside an authorized clinical trial or an approved expanded-access request may be illegal in your jurisdiction. Consult a licensed physician for personal medical decisions.
What Changed on August 3
Nothing about retatrutide's regulatory status changed. What changed is that Lilly acknowledged a pathway exists and started reviewing physician requests through it.
The trigger was a one-off grant in April 2026. Dr. Ranganath Muniyappa, a clinician at the National Institutes of Health, filed an individual-patient expanded-access request with the FDA on behalf of a 79-year-old man with refractory obesity, obstructive sleep apnea, and pulmonary hypertension. STAT News reported the case on June 23, and it drew political scrutiny — enough that the White House publicly denied the patient was the president. We covered that case and its fallout in One Person Got Retatrutide Early.
What followed was a wave of physician inquiries that Lilly initially did not answer. Doctors at the online obesity clinic Vineyard told reporters they had applied on behalf of multiple patients who had not responded adequately to tirzepatide at maximum dose, and had gone weeks without a substantive reply. The August 3 confirmation was, as one outlet put it, a notable departure from the company's earlier silence about whether a program existed at all.
The Four Criteria
Per reporting on the program's requirements, an applicant must clear all four of the following. They are cumulative, not alternatives.
| Requirement | What it means in practice |
|---|---|
| Age 18 or older | Straightforward; excludes the adolescent obesity population entirely. |
| Treatment-resistant obesity | Documented inadequate response to approved therapy — in most reported cases, failure at the maximal tolerated dose of tirzepatide or a GLP-1 agonist. |
| At least two serious or life-threatening obesity-related complications | The bar reported for the original April grant was obstructive sleep apnea plus pulmonary hypertension. Two comorbidities, both serious. |
| Unable to enroll in a clinical trial or access a comparable treatment | If a retatrutide trial is recruiting within reach, or an approved drug is still an option, the request fails on its face. |
The fourth criterion is the one that quietly eliminates the most people. Lilly's TRIUMPH and TRANSCEND programs are large and still enrolling in many regions, and "comparable treatment" includes approved incretin drugs the applicant has not yet exhausted. A person who simply wants a more effective drug than the one they are on does not meet the definition.
Reporting has been blunt that the net effect is a program most applicants cannot satisfy — the criteria describe a patient who is simultaneously sick enough to justify an unapproved biologic and unable to reach any of the approved or investigational alternatives.
Three Gatekeepers, No Coordination
Even a qualifying patient does not have a single application to complete. Expanded access under FDA rules requires three independent sign-offs:
- The treating physician files the request. Patients cannot self-apply; a clinician has to be willing to sponsor it, take on the documentation, and accept the oversight burden.
- Lilly must agree to supply the drug. This is the step that has no statutory obligation behind it — the FDA can authorize an expanded-access request, but a manufacturer is never required to fill it.
- The FDA and an institutional review board must each authorize the protocol.
Reporting on the process has emphasized that these three tracks do not talk to each other and that there is no appeals mechanism if any one of them says no. Lilly's published expanded-access policy commits to a response within five business days of receiving the required medical information, but physicians describing their experience in August put the real-world wait at weeks. The company has not disclosed how many requests it intends to approve, how long an approved patient could stay on treatment, or who pays for the drug.
That last omission matters. Expanded access does not come with an insurance pathway, and manufacturers may charge only direct costs — or nothing — at their discretion. Neither has been specified here.
What This Means for Buyers
For the overwhelming majority of people searching for retatrutide, the practical answer is unchanged: there is no legal prescription route. The expanded-access program is a narrow clinical carve-out for severe, treatment-resistant cases, not a distribution channel. And the approval timeline moved away from the reader, not toward them — Lilly pushed its regulatory submission to Q1 2027, which puts a realistic approval in late 2027 or 2028.
Meanwhile the compound circulates in the research-chemical market, where it is sold labeled for laboratory use only and not for human consumption. It is not FDA-approved, no agency verifies purity or intended use, and it is not legally prescribable. Buyers researching that market generally compare two things: third-party certificate-of-analysis (COA) testing and price per milligram. Vendor listings are commonly catalogued at 10 mg and larger vial sizes, which is what the per-milligram comparisons below are normalized against. Ascension Peptides currently runs a standing 50% discount, with EZ Peptides and Ion Peptide close behind on COA-backed per-milligram pricing.
Compare live pricing and COA status: Best Retatrutide Vendors ranks in-stock sources on price, testing, and reputation, and the current vendor coupons page lists active discount codes across tracked vendors.
This article contains affiliate links; The Peptide Catalog may earn a commission if you purchase through them. Retatrutide is sold for research use only and is not FDA-approved for human use.
